JPMorgan analyst Anupam Rama downgraded iTeos Therapeutics (ITOS) to Neutral from Overweight.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics Ends Collaboration with GSK
- GSK, iTeos ending development program for belrestotug
- iTeos Therapeutics, GSK agree to terminate belrestotug development program
- iTeos Therapeutics initiates targeted review of strategic alternatives
- iTeos: GALAXIES Lung-201 did not meet criteria for meaninful improvements in PFS